Pyxis Oncology, Inc.
PYXS
$3.37
-$0.63-15.75%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.82M | 2.82M | 0.00 | 16.15M | 16.15M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.82M | 2.82M | 0.00 | 16.15M | 16.15M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 475.00K | 475.00K |
| Gross Profit | 2.82M | 2.82M | 0.00 | 15.67M | 15.67M |
| SG&A Expenses | 19.44M | 19.78M | 20.40M | 22.49M | 23.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.45M | 85.73M | 83.16M | 81.72M | 80.52M |
| Operating Income | -82.63M | -82.91M | -83.16M | -65.57M | -64.37M |
| Income Before Tax | -98.97M | -98.17M | -97.40M | -79.50M | -57.36M |
| Income Tax Expenses | -1.88M | -1.88M | -2.16M | -2.16M | -- |
| Earnings from Continuing Operations | -97.09 | -96.29 | -95.23 | -77.33 | -57.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -97.09M | -96.29M | -95.23M | -77.33M | -57.36M |
| EBIT | -82.63M | -82.91M | -83.16M | -65.57M | -64.37M |
| EBITDA | -80.47M | -80.54M | -80.75M | -62.59M | -61.25M |
| EPS Basic | -1.58 | -1.57 | -1.56 | -1.28 | -1.05 |
| Normalized Basic EPS | -0.79 | -0.79 | -0.78 | -0.61 | -0.66 |
| EPS Diluted | -1.58 | -1.57 | -1.56 | -1.28 | -1.05 |
| Normalized Diluted EPS | -0.79 | -0.79 | -0.78 | -0.61 | -0.66 |
| Average Basic Shares Outstanding | 246.77M | 244.93M | 243.51M | 233.75M | 216.98M |
| Average Diluted Shares Outstanding | 246.77M | 244.93M | 243.51M | 233.75M | 216.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |